Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was found to induce longer responses than the into-the-vein formulation. These findings were shared in an oral presentation at the 62nd American Society of Hematology Annual Meeting and…
You must be logged in to read/download the full post.
The post Under-the-skin Velcade Found to Work Better in Farydak Triple Combo appeared first on BioNewsFeeds.